Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints head of research

Yong-Jun Liu to lead R&D at AstraZeneca biologics subsidiary

MedImmune Jong-Jun LiuAstraZeneca (AZ) has strengthened its research team by appointing leading academic Dr Yong-Jun Liu as head of research at its MedImmune subsidiary.

AZ has made of series of pipeline-boosting acquisitions in the past year, but the appointment of Dr Liu is a move to strengthen its existing R&D operations.

Dr Liu joins the company after an extensive career in academia, which most recently saw him serve as VP and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute for Immunology Research.

He also served for a period as chair of the Department of Immunology at the University of Texas.

MedImmune focuses on the development of biologics and will look to benefit from Dr Liu's experience in immunology as it works to develop a portfolio of immunotherapies, including investigational cancer treatments.

Bahija Jallal, executive VP MedImmune, commented on the company's commitment to develop in-house research through strong leadership.

“Scientific leadership is our top priority,” said Jallal. “We are committed to hiring established leaders who will drive our research engine and progress our efforts to deliver valuable medicines to patients.”

18th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics